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Background: The Cancer/Testis Antigens (CTAs) are a heterogeneous group of proteins whose expression is
typically restricted to the testis. However, they are aberrantly expressed in most cancers that have been examined
to date. Broadly speaking, the CTAs can be divided into two groups: the CTX antigens that are encoded by the
X-linked genes and the non-X CT antigens that are encoded by the autosomes. Unlike the non-X CTAs, the CTX
antigens form clusters of closely related gene families and their expression is frequently associated with advanced
disease with poorer prognosis. Regardless however, the mechanism(s) underlying their selective derepression and
stage-specific expression in cancer remain poorly understood, although promoter DNA demethylation is believed to
be the major driver.
Methods: Here, we report a systematic analysis of DNA methylation profiling data from various tissue types to
elucidate the mechanism underlying the derepression of the CTAs in cancer. We analyzed the methylation profiles
of 501 samples including sperm, several cancer types, and their corresponding normal somatic tissue types.
Results: We found strong evidence for specific DNA hypomethylation of CTA promoters in the testis and cancer
cells but not in their normal somatic counterparts. We also found that hypomethylation was clustered on the
genome into domains that coincided with nuclear lamina-associated domains (LADs) and that these regions
appeared to be insulated by CTCF sites. Interestingly, we did not observe any significant differences in the
hypomethylation pattern between the CTAs without CpG islands and the CTAs with CpG islands in the proximal
promoter.
Conclusion: Our results corroborate that widespread DNA hypomethylation appears to be the driver in the
derepression of CTA expression in cancer and furthermore, demonstrate that these hypomethylated domains are
associated with the nuclear lamina-associated domains (LADS). Taken together, our results suggest that wide-spread
methylation changes in cancer are linked to derepression of germ-line-specific genes that is orchestrated by the
three dimensional organization of the cancer genome.
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The Cancer/Testis Antigens (CTAs) are a group of tumor-
associated proteins that are typically expressed in normal
male germ cells but are silent in normal somatic cells.
However, they are aberrantly expressed in several types of
cancers [1,2]. Because of this unique expression pattern, the
CTAs are considered attractive targets for cancer bio-
markers and immunotherapy [3].
Broadly speaking, the CTAs can be divided into two
groups: the CTX antigens that are encoded by the X
chromosome and the non-X CT antigens that are encoded
by the autosomes. To date, 228 CTAs have been identified
of which 120 CTAs (52%) map to the X chromosome (the
CTX antigens) while the remaining (non-X CT antigens),
are distributed on the 22 autosomes and the Y chromosome
[4]. Interestingly, while some autosomes that are gene-poor
such as chromosome 21 (only 425 genes), are enriched for
CTA genes (1.6 CTAs/100 genes), others, that are gene-
rich, such as chromosome 1 (3380 genes) and 7 (1764
genes), are very CTA-poor with only 0.3 CTAs and 0.06
CTAs/100 genes, respectively. However, among the sex
chromosomes, while only 1 CTA is present on the Y
chromosome, there are 7.5 CTAs/100 genes on the X
chromosome – a 125-fold increase over chromosome 7 [4].
Furthermore, the CTX antigens are comprised of large
gene families of closely related members and are fre-
quently associated with advanced disease with poorer
prognosis [5-10]. It is remarkable that as much as 10%
of the genes on the X chromosome are estimated to be-
long to CT-X families [11]. Although the role of many of
these tumor-associated antigens in the disease process
remains unclear, emerging evidence indicates that they
appear to function in several important cellular pro-
cesses such as transcriptional regulation, signal trans-
duction, and cell growth [3]. Some also appear to
function as putative proto-oncogenes [12,13] and are as-
sociated with maintaining the undifferentiated state of
stem cells [14-17].
More recently, a majority of the CTAs, especially the
CTX antigens, were predicted to be intrinsically disordered
proteins or IDPs [4]. IDPs are proteins that lack a rigid
structure at least in vitro. Despite the lack of structure,
most IDPs can transition from disorder to order upon bind-
ing to biological targets and often promote highly promis-
cuous interactions. Thus, IDPs play important roles in
transcriptional regulation and signaling via regulatory pro-
tein networks and are frequently over-expressed in patho-
logical conditions such as cancer [18,19]. Consistent with
these observations, several CTAs are predicted to bind to
DNA and their forced expression appears to increase cell
growth implying a potential dosage-sensitive function [4].
Taken together, these observations provide a novel perspec-
tive on the CTAs implicating them in processing and trans-
ducing information in altered physiological states in adosage-sensitive manner. Thus, understanding how the
CTAs are selectively derepressed in cancer is an important
question in cancer biology.
Although the mechanism promoting their derepression is
not entirely clear, it is widely held that DNA methylation is
one of the central mechanisms responsible for gene silen-
cing [20-22]. For example, De Smet et al. have observed se-
lective and genome-wide hypomethylation of MAGE-A1,
one of the most studied CTAs in cancer cells, coincided
with its activation [23-25]. Several other studies have also
reported a similar trend in other CTA genes [26-30].
Roman-Gomez et al. discovered direct correlation between
the methylation levels of the HAGE gene and its expression
in myeloid leukemia [29]. Similarly, Cho et al. observed
expression of the CAGE gene and its promoter hypo-
methylation in gastric cancer [27]. Yegnasubramanian et al.
found that although the CT-X antigens undergo DNA
hypomethylation and overexpression in primary prostate
cancers, these changes were more pronounced in meta-
static disease when many CT-X antigens were highly
upregulated coincident with poorer prognosis [30]. Consist-
ent with this hypothesis, other studies have shown that
inhibiting DNA methyltransferase (DNMT) activity with 5
aza-deoxycytidine (5 AZA) results in robust somatic ex-
pression of a set of CTAs both in vitro and in vivo [31].
However, only a few studies have experimentally confirmed
promoter demethylation following DNMT inhibition by
5AZA or silencing by siRNA [13,32] and in many cases
CTA genes that lack CpG dinucleotides respond to DNMT
inhibition while in other cases, despite the presence of CpG
dinucleotides, the CTA genes are not derepressed. For in-
stance, the SPANX genes, which lack a CpG island in the
promoter region [33], respond robustly to 5 AZA treat-
ments [34] implicating an indirect mechanisms underlying
the response, although the presence of such sites at distal
regions or within introns cannot be ruled out. It is therefore
unclear to what extent these effects are mediated directly
by promoter demethylation of the target genes as opposed
to being indirectly driven by demethylation in conjunction
with transcription factors that activate CTA expression.
Thus, it is obvious that our understanding of CTA gene
regulation and mechanisms underlying their abrupt dere-
pression in cancer has been not subjected to a genome-
wide analysis to assess their generality. Such a genome-wide
analysis has recently become possible due to availability
of genome-scale methylation arrays and other related
technologies. Here, using genome-scale methylation
profiles of promoter CpG methylation in 501 samples that
included 305 normal sperm and somatic cells, and 196
cancers, we employed a new metric to identify gene pro-
moters that follow an expected pattern of CTA promoter
methylation, i.e., promoters that are unmethylated in
sperm, methylated in somatic tissues, but unmethylated in
cancer tissues. The higher the metric value for a gene
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methylation pattern (PMP). Our analysis confirmed that
CTA gene promoters broadly follow a PMP. At the gen-
ome level, we observed that PMP promoters tend to clus-
ter together on the genome and the CTA genes appeared
to strongly associate with such clusters. Furthermore, we
discovered that the binding sites for CTCF, the generic ‘in-
sulator protein’, demarcate the regions of PMP. Genomic
regions with PMPs have been observed to be enriched for
genes involved in defense response, immune response,
and cytokine-cytokine receptor interaction [35,36]. We
also found that a large fraction of CTAs genes, especially
the ones associated with clusters of PMPs coincided with
the nuclear lamina-associated domains (LADs). However,
we did not observe any significant differences in the above
hypomethylation patterns between the promoters with
CpG islands (CGI) and promoters without CpG islands
(non-CGI). Taken together, our results indicate that PMP
is a broad phenomenon covering CTAs and that their de-
repression is significantly explained by previously ob-
served broad domains of hypomethylation in cancer that
are associated with LADs.
Methods
Methylation data
DNA methylation profiling data were obtained from
the Gene Expression Omnibus (GEO) database [37]. To
be consistent, methylation profile datasets from only
one platform, Illumina HumanMethylation27 BeadChip
(GPL8490) containing 27578 genome-wide promoter CG
dinucleotides, was used in this study. Our methylation
dataset contained 501 samples from profiling studies for
five different tissues and conditions: breast cancer tis-
sues (GSE26990), colorectal cancer tissues (GSE25062,
GSE17648), normal sperm (GSE26974), and prostate can-
cer tissues (GSE26126). The processed and normalized
data was used as provided. The CG loci were partitioned
into two groups based on whether it belonged to a CpG
islands (CGIs; 16561 loci) or not (non-CGIs; 11017 loci).
Human CGIs were obtained from the UCSC Genome
Browser (genome.ucsc.edu; Build 36, hg18).
Estimating delta-PMP for a CTCF site
For each CTCF location, three nearest genes (by their
transcription start sites) 5’ of the CTCF site and three
nearest genes 3’ of the CTCF site were determined using
ENSEMBL gene annotation (www.ensembl.org). A CTCF
site was included for the analysis, if at least one of the
three promoters to the left of the CTCF site and at least
one of the three promoters to the right of the site had a
CG locus represented in the methylation dataset. We
computed the average PMP-sim for the promoters to the
left and average PMP-sim for the promoters to the right.
Then, we computed the absolute difference of those twoaverages as delta-PMP. The above procedure was per-
formed separately for CGI loci and non-CGI loci.
Results
Method overview
Table 1 provides a summary of the Gene Expression Omni-
bus (GEO) datasets used in this study. Overall, the datasets
included 501 distinct samples across 27578 CpG loci in the
genome based on the HumanMethylation27 BeadChip data
(Illumina, CA). Out of 501 samples, 289 (58%) of them
were from tumors, while 212 (42%) were normal. Thus, the
data is summarized as a matrix with 27578 rows and 501
columns with methylation intensity. As shown in Figure 1,
we defined a prototypical methylation pattern (PMP) vector
with 501 entries, one per sample, as follows. For each sam-
ple i, (1) if the sample was obtained from either normal
sperm cells or a cancer tissue, then the minimum methyla-
tion value of all the genes for that sample was assigned to
the ith entry in PMP vector, and (2) if the sample was
obtained from a normal somatic tissue, then the maximum
methylation value of all the genes for that sample was
assigned to the ith entry in PMP vector. The PMP vector
values are reported in Additional file 1: Table S1.
To quantify how well a particular CpG location j con-
forms to the PMP, we computed the Pearson correlation
between the jth row and the PMP-vector; we refer to this
as PMP-sim or Sj. A high value of Sj, indicates that the
CpG location is methylated in normal somatic cells and
unmethylated in sperm and cancer cells.
CTA and CTX gene promoters have prototypical
methylation patterns
We computed the PMP-sim for all 27578 loci of which 92
correspond to non-X CTA genes (hereon referred to as
CTA) and 47 correspond to CTX genes. Overall, the aver-
age PMP-sim values was −0.014 ± 0.17, while for the CTA
and the CTX genes the average PMP-sim was 0.18 ± 0.17
and 0.27 ± 0.087 respectively (Figure 2). The difference be-
tween CTA and all genes was highly significant with
Mann–Whitney U test p-value = 1.47E-21, and likewise for
CTX versus all genes with p-value = 1.16E-23. Furthermore,
the difference between CTX and CTA was also significant
(p-value = 0.002). We have provided a heatmap (Additional
file 2: Figure S1) which clearly shows the prototypical
methylation patterns of CTA and CTX genes across 501
samples. Furthermore, we have also demonstrated that sev-
eral well-known CTAs (MAGE, XAGE, PAGE, and GAGE
families) follow the prototypical pattern closely (Additional
file 3: Figure S2). All four families had significantly high
PMP-sim values: MAGE family (n = 19; PMP-sim = 0.27 ±
0.092), XAGE family (n = 2; PMP-sim = 0.22 ± 0.045), PAGE
family (n = 4; PMP-sim = 0.22 ± 0.052), and GAGE family
(n = 2; PMP-sim = 0.30 ± 0.038). Our conclusion does not
change when we constructed the PMP vector by assigning
Table 1 GEO methylation studies included for analysis
GEO accession Tissue type Total samples Normal samples Tumor samples
GSE26990 Breast** 89 42 47
GSE26126 Prostate 193 98 95
GSE17648 Colorectal 44 22 22
GSE25062 Colorectal 154 29 125
GSE26974 Sperm 21 21 0
All methylation profiling was done based on Illumina HumanMethylation27 BeadChip (GEO platform GPL8490).
** Also included nine normal samples from other tissues (blood, spleen, colon, fetal brain, liver, testis, embryo, and adult brain).
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to normal somatic cells.
In genome-wide profiling of gene expression and other
studies such as DNA methylation, laboratory-specific biases
are a significant concern. A visual inspection of the methy-
lation profiles organized by GEO series indicated such a
bias. To ensure that our conclusion regarding a greater
PMP-sim value for CTA and CTX is not simply because of
this bias, we performed the following control. For each CG
locus, within each GEO series (Table 1), we randomly per-
muted the samples. This has the effect of randomizing the
normal/tumor identity of the sample while preserving the
lab-specific (series-specific) biases. If our observed results
above are primarily due to laboratory-specific biases thenFigure 1 Scheme to determine prototypical methylation pattern (PMP
samples. For each sample, if it is cancer or sperm sample, the correspondin
among all 27578 CG loci for that sample, and if the sample is from normal
assigned the maximum methylation value among all 27578 CG loci for tha
samples, the Pearson correlation between the methylation pattern and thewe would expect the PMP-sim values to be largely pre-
served. We found this not to be the case. While overall, the
PMP-sim did not change significantly (going from 0.014 ±
0.17 for original data to 0.01 ± 0.10 for the permuted data),
the PMP-sim for CTA loci was significantly reduced from
0.18 ± 0.17 to 0.03 ± 0.11and that for the CTX genes signifi-
cantly reduced from 0.27 ± 0.09 to 0.06 ± 0.10. Thus, we
conclude that our observed elevated PMP-sim for CTA/
CTX loci is not simply due to laboratory-specific biases.
Next, to assess the robustness of our findings above, of
the 501 total samples, we randomly sampled 70 samples:
10 normal breast samples (GSE26990), 10 breast can-
cer samples (GSE26990), 10 normal prostate samples
(GSE26126), 10 prostate cancer samples (GSE26126), 10) and PMP-sim. PMP is a vector or length 501 corresponding to 501
g PMP vector element is assigned the minimum methylation value
somatic tissue cancer the corresponding PMP vector element is
t sample. For any CG locus, given its methylation pattern across 501
PMP-vector is used to estimate PMP-sim for the CG locus.
Figure 2 Pearson correlation values for the CTX and CTA genes are significantly high. (A-B) Pearson correlation distribution in three
groups: all the loci (n = 27578), CTX loci (n = 47), and CTA loci (n = 92). A box and whisker plot comparing the correlation values among the three
loci groups is shown in (B). The plot shows the median, the mean (crosses inside the boxes), 25th percentile (bottom line of the box), 75th
percentile (top line of the box), and minimum and maximum values as whiskers. (C-D) Pearson correlation distribution in three groups: all the loci
(n = 27578), CTX loci in CGI regions (n = 4), and CTA loci in CGI regions (n = 36). (E-F) Pearson correlation distribution in three groups: all the loci
(n = 27578), CTX loci in non-CGI regions (n = 43), and CTA loci in non-CGI regions (n = 56).
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samples (5 from GSE17648 and 5 from GSE25062), and
10 colorectal cancer samples (5 from GSE17648 and 5
from GSE25062). Using these randomly chosen 70 sam-
ples instead of 501 samples as above, we computed the
PMP-sim for all 27578 loci again and observed high PMP-
sim values for the CTA and CTX genes. The results were
highly consistent with those obtained when using all 501
samples. The average PMP-sim value across all the loci de-
creased slightly (going from 0.014 ± 0.17 for the original
data to −0.003 ± 0.21 for the re-sampled data). The aver-
age PMP-sim values for the CTA and CTX genes were
0.18 ± 0.18 (0.18 ± 0.17 for the original data) and 0.25 ± 0.09(0.27 ± 0.09 for the original data), respectively. Thus, the
results support the robustness of the greater PMP-sim
observed for the CTA/CTX loci.
We then partitioned the 27578 promoter CG dinucleo-
tides into 16561 that resided within a CpG island (CGI)
and the rest 11017 that did not (non-CGI). Corresponding
CGI and non-CGI, counts for CTA genes were 36 and 56
and those for CTX were 4, and 43, respectively. We re-
peated the above analyses separately for CGI and non-CGI
promoters and the results were similarly significant
(Figure 2): all genes vs. CGI CTA (Mann–Whitney U test
p-value = 0.0048), all genes vs. CGI CTX (p-value = 0.0011),
all genes vs. non-CGI CTA (p-value = 2.00E-23), and all
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sults suggest that CTA promoters largely follow a PMP
across various tissues in both CGI and non-CGI promoters.
However, the number of CGI CTX loci was very small,
even though the tests showed statistical significance.
Promoters that follow prototypical methylation pattern
are clustered on the genome
To further understand the mechanism underlying the
PMP, we next tested whether the CG dinucleotides that
follow PMP, i.e. have high PMP-sim, are clustered on the
genome. We identified CG dinucleotides with PMP-sim in
top 20th percentile; we refer to this set as high-PMP. We
constructed a binary vector of length 27578 corresponding
to all CG dinucleotides sorted by their genomic locations.
We assigned a ‘1’ at locations corresponding to high-PMP
CGs and ‘0’ to the rest. In this binary vector, a run was de-
fined as consecutive ‘1’s and the length of a run as the
number of consecutive ones in the vector. We identified
the runs and their lengths separately for CGIs and non-
CGIs promoters. Long runs are suggestive of genomic
clustering of PMP promoters. As a control we randomly
permuted the binary vector. As shown in Figure 3, we
found that for both CGIs and non-CGI promoters the run
lengths were significantly higher than that for the corre-
sponding controls (Mann–Whitney U test p-value =Figure 3 PMP run lengths for CGIs and non-CGIs were higher than th
are shown for (A) CGIs, (B) randomized CGIs as a control group for (A), (C)0.0001 for CGIs and 1.47E-12 for non-CGIs). The average
run length for CGIs was 2.348 ± 0.722 (range 1 – 9), and
1.241 ± 0.533 (range 1 – 5) in permuted control. The aver-
age run length for non-CGIs was slightly higher at 2.669 ±
1.358 (range 1 – 15) and the corresponding control had
run lengths 1.254 ± 0.556 (range 1 – 4). CGIs had 633 runs
(26%) with length of two or greater out of 2460 runs. Non-
CGIs had 429 runs (28%) with length of two or greater out
of 1488 runs. These results, summarized in Figure 3, sug-
gest that promoters with PMP are clustered on the genome
for both CGI and non-CGI promoters.
CTA and CTX gene promoters reside largely within
PMP runs
Next, we assessed the extent to which CTA and CTX genes
reside within runs of promoters with PMP. As shown in
Table 2 for both CGIs and non-CGIs, the fractions of CTA
and CTX genes residing within runs were significantly
higher than their control groups (binary vectors from run-
of-ones analysis permuted 100 times). All comparisons
using z-score statistics yielded p-value < 4.72E-12. It is also
interesting to note that the fractions of CTA and CTX loci
that are part of a run (referred to as CTA-F and CTX-F in
Table 2) from non-CGIs were far greater than those from
CGIs. In other words, more CTA and CTX genes from
non-CGIs comprised the runs of length two or greater.e random control. Distribution of runs with length of two or greater
non-CGIs, and (D) randomized non-CGIs as a control group for (C).
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CCCTC-binding factor (CTCF) is a multifunctional protein
best known for its role as an insulator of epigenomic marks
[38,39]. Thus, we asked whether the presence of CTCF
binding sites has any bearing on PMP at consecutive CG
loci intervened by CTCF binding. A previous study com-
paring CTCF binding in multiple cell types had shown that
a large fraction of CTCF binding events are conserved
across cell types [40]. Thus, in our analysis we only in-
cluded 7428 CTCF sites that were common to 4 cell types,
namely CD4+ T cell, IMR90, Hela, and Jurkat. Details of in-
dividual datasets and extraction method are provided in
[40]. For each CTCF binding site we assessed its insulator
tendency as the absolute difference in average PMP-sim be-
tween 3 CG loci to the 5’ of the CTCF site and 3 CG loci to
the 3’ of the CTCF site (see Methods); we refer to this value
as delta-PMP. As a control for CTCF sites, we chose ran-
dom loci in the genome.
Interestingly, we found that for both CGIs and non-
CGIs promoters, the delta-PMP for CTCF sites were sig-
nificantly higher than the random control (Figure 4).
The average delta-PMP for CGIs was 0.12 ± 0.09, while
the random delta-PMP was 0.062 ± 0.05 (Mann–Whitney
U test p-value = 1.38E-217). A similar trend was observed
in non-CGIs; the mean CTCF delta was 0.12 ± 0.09, while
the mean random delta was 0.07 ± 0.05 (Mann–Whitney
U test p-value =7.59E-52). Moreover, the delta-PMP dis-
tribution of CGIs and non-CGIs was statistically indistin-
guishable. Further, when we tested whether the CTAs or
runs of CTAs reside near a CTCF site relative to random
expectation, we found this not to be the case, suggesting
that potential involvement of CTCF sites in demarcating
PMP regions is not relevant to CTAs and is instead a gen-
eral phenomenon.Promoters with PMP intersect with Lamin Attachment
Domains (LADs)
Regions of hypomethylation in cancer have previously been
shown to significantly intersect with LADs and are thusTable 2 Fractions of CTA and CTX genes in CGIs and
non-CGIs that are in runs with length of two or greater
CGIs
Original Binary Vector Permuted Binary Vector
(avg. ± sd.)
CTA-F CTX-F CTA-F CTX-F
0.250 (9 out of 36) 1 (4 out of 4) 0.013 ± 0.0248 0.0175 ± 0.0815
Non-CGIs
Original Binary Vector Permuted Binary Vector
CTA-F CTX-F CTA-F CTX-F
0.786 (44 out of 56) 0.884 (38 out of 43) 0.226 ± 0.081 0.223 ± 0.077thought to be critical in organizing the interphase chromo-
somes [41]. We extracted 1344 LAD loci from [42]. Out of
5397 high-PMP (CGI and non-CGI loci combined) 1389
(25.74%) resided within a LAD, and of the 21558 other CG
loci only 3229 (14.98%) resided within a LAD. This differ-
ence was statistically highly significant (Fisher’s exact test
p-value = 8.17E-50). The difference is similarly significant
when CGI and non-CGI loci were analyzed separately. This
result along with our finding that CTA (and CTX) CG loci
have high PMP-sim would suggest a high correlation be-
tween CTAs and LADs. This is indeed the case and as
shown in Figure 5, the fraction of CTA and CTX loci, both
overall, as well as the ones that intersect with high-PMP
runs, intersect with LAD regions five- to six-fold more
frequently than random expectations: all comparisons
using z-score statistics yielded an extremely small p-value
(almost 0). In addition, we found that the CG loci within
LADs had significantly greater PMP-sim values than the
CG loci outside LADs (Mann–Whitney U test p-value =
8.20E-31). Thus, our results suggest that high-PMP runs,
and consequently CTA and CTX loci with PMPs largely
intersect with LAD regions.
Given that CTCF sites demarcate PMP from non-PMP
regions, that PMP regions overlap with LAD, and that LAD
were previously shown to be demarcated by CTCF sites
[42], we expect that LAD boundaries themselves demarcate
PMP from non-PMP regions. Similar to our previous ana-
lysis performed on the CTCF binding sites, we assessed the
tendency of LAD boundaries to exhibit high difference in
PMP-sim for the three CG loci to the 5’ and the three CG
loci to the 3’. As expected we observed a trend similar to
that observed for CTCF sites. The delta-PMP values for
LAD boundary loci were significantly higher than the ran-
dom control for both CGIs and non-CGIs promoters. The
average delta-PMP for LAD loci in CGIs was 0.11 ± 0.089,
while the control delta-PMP was 0.063 ± 0.052 (Mann–
Whitney U test p-value = 8.27E-30). The average delta-
PMP for LAD loci in non-CGIs was 0.11 ± 0.094, while its
control delta-PMP was 0.071 ± 0.055 (p-value = 2.43E-7).
Discussion
Even amongst the so-called tissue-specific genes, the CTAs
exhibit a remarkable expression pattern. While typically
expressed only in the sperm and repressed in normal som-
atic tissues, they are aberrantly derepressed in most cancers
[1]. However, neither the mechanism nor the functional
consequence of this atypical expression pattern is entirely
clear for most, if not all, CTAs. While there is evidence to
suggest that promoter demethylation might be a major
driver of derepression of CTA expression in cancer [3], this
mechanism does not appear to be universally applicable to
all CTAs [34]. Independent of CTA-related investigations,
it has been shown that large genomic regions are
hypomethylated in some cancers [41,43]. It is therefore
Figure 4 Delta-PMP values for the CTCF sites in CGIs and non-CGIs were higher than the random control. (A) delta-PMP distribution for
the CTCF sites in CGIs (red) and its control (blue). (B) delta-PMP distribution for the CTCF sites in non-CGIs (red) and its control (blue).
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global hypomethylation as bystanders leading to their dere-
pression. Based on a systematic analysis of DNA methyla-
tion profiling data from various tissues, our results support
this thesis.
We found specific hypomethylation of the CTA and
CTX promoters in the testis and cancer cells. More
specifically, we observed hypomethylation of MAGE,
XAGE, PAGE, and GAGE promoters in cancer samples
(Additional file 3: Figure S2) confirming several studies
that have reported that the activation of these genes in
cancer is strongly correlated with promoter demethylation
[23,44,45]. This result, combined with well-established as-
sociation between DNA methylation and gene silencing
suggests methylation as the predominant mechanism for
CTA derepression in cancers. Moreover, the loci with
PMP including the ones in CTA and CTX promoters,Figure 5 CTA and CTX loci intersect with LAD regions more
frequently. Out of 92 CTA loci, 47 (51.09%) resided within a LAD
(red bar); Out of 19 CTA loci in PMP runs, 12 (64.16%) of them
resided within a LAD (blue bar); Out of 47 CTX loci, 32 (68.09%)
resided within a LAD (purple bar); Out of 12 CTX loci in PMP runs, 8
(66.67%) of them resided within a LAD (green bar). Out of 1000 loci
randomly selected, 173 (17.30%) resided within a LAD (orange bar).cluster on the genome and are associated with LAD re-
gions. This is consistent with broad regions of hypo-
methylation in cancers that are also associated with LAD
regions [41]. Taken together, these findings suggest that
hypomethylation and derepression of CTA and CTX
genes in cancers are part of a broader phenomenon and
may not depend on a specific mechanism. We also found
that the broad tendencies revealed by our analyses are
independent of CpG islands. This may suggest a non-
specific mechanism underlying methylation-mediated de-
repression of CTA genes. Furthermore, we also found that
CTCF sites are linked to a sudden change in methylation
patterns for both CGIs and non-CGI loci. This is consist-
ent with a previous study that found epigenetic silencing
of tumor suppressor genes in the absence of CTCF bind-
ing [46].
We note that the methylation profiling platform (Illumina
HumanMethylation27 BeadChip) used in this study in-
cludes only ~1 CpG locus per gene promoter, resulting in a
small number loci corresponding to CTA and CTX genes.
Furthermore, a single CpG site may not be representative
of an entire promoter in all cases. Although Illumina has a
newer and denser methylation chip (Illumina Human
Methylation450 BeadChip) which contains more than
450,000 methylation sites, the number of relevant tissues
for which such data exists is currently insufficient. In
addition, although previous works have illustrated an in-
verse correlation between promoter methylation and gene
expression level, we could not ascertain this for our data
because none of the samples included in the study had a
corresponding expression data available.
Conclusions
In conclusion, here we present a systematic analysis based
on large number of genome-wide methylation profiles
across multiple normal and tumor cells demonstrating that
in general, derepression of CTA and CTX genes in cancer
may be largely explained by global hypomethylation medi-
ated by disruption of laminar attachment regions. However,
it is important to note that, DNA hypomethylation may not
Kim et al. BMC Cancer 2013, 13:144 Page 9 of 10
http://www.biomedcentral.com/1471-2407/13/144be the only mechanism since several CTAs lacking CpG
islands are also upregulated in response to DNA hypo-
methylation [47]. Thus, it is possible that at least for some
CTA genes, additional mechanisms for repression and al-
ternative mechanisms for derepression in cancer exist
which may involve specific repressive or activating tran-
scription factors. Additional biochemical studies elucidating
global methylation changes should yield new insights on
regulation of CTA expression paving the way to the devel-
opment of novel therapeutic modalities for cancer. This is
particularly important since epigenetic modulation of CTA
expression is emerging as a novel medical modality for can-
cer immunotherapy [32,48,49].
Additional files
Additional file 1: Table S1. The PMP vector for 501 samples is shown
in the file.
Additional file 2: Figure S1. Heatmap of the methylation levels of CTA,
CTX, and non-CTA loci across 501 samples. Heatmap of methylation data
shows the prototypical methylation patterns of CTA and CTX loci: high
methylation levels (yellow in the heatmap) in normal samples and low
methylation levels (green in the heatmap) in cancer and sperm cells. On
the other hand, the methylation levels of 150 randomly selected non-
CTA loci did not follow the prototypical methylation patterns.
Additional file 3: Figure S2. Heatmap of the methylation levels of
MAGE, XAGE, PAGE, and GAGE promoter loci across 501 samples.
Heatmap of methylation data shows that these four CTX families follow
the prototypical methylation patterns: high methylation levels (yellow in
the heatmap) in normal samples and low methylation levels (green in
the heatmap) in cancer and sperm cells. The average PMP-sim values for
the four families are: 0.27 ± 0.092 (MAGE family; n = 19), 0.22 ± 0.045
(XAGE family; n = 2), 0.22 ± 0.052 (PAGE family; n = 4), and 0.30 ± 0.038
(GAGE family; n = 2). The PMP vector is shown in the bottom part of the
figure (boxed), and the PMP-sim value for each gene is shown on the
right vertical axis.
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